215 related articles for article (PubMed ID: 24702855)
1. Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease in patients with advanced non-small-cell lung cancer.
Asai N; Yamaguchi E; Kubo A
Clin Lung Cancer; 2014 May; 15(3):e33-5. PubMed ID: 24702855
[No Abstract] [Full Text] [Related]
2. Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease.
Tachihara M; Kobayashi K; Ishikawa Y; Hori S; Tamura D; Otera H; Funada Y; Nishimura Y
Jpn J Clin Oncol; 2014 Aug; 44(8):762-4. PubMed ID: 24872405
[TBL] [Abstract][Full Text] [Related]
3. Crizotinib-induced acute interstitial lung disease in a patient with EML4-ALK positive non-small cell lung cancer and chronic interstitial pneumonia.
Watanabe N; Nakahara Y; Taniguchi H; Kimura T; Kondoh Y; Kataoka K; Sakamoto K
Acta Oncol; 2014 Jan; 53(1):158-60. PubMed ID: 23750540
[No Abstract] [Full Text] [Related]
4. Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer.
Tamiya A; Okamoto I; Miyazaki M; Shimizu S; Kitaichi M; Nakagawa K
J Clin Oncol; 2013 Jan; 31(1):e15-7. PubMed ID: 23169500
[No Abstract] [Full Text] [Related]
5. Severe acute interstitial lung disease induced by crizotinib therapy in a patient with c-Met amplification non-small cell lung cancer.
Ji Y; Zhang Z; Nie K; Lan K; Geng C; Liu S; Zhang L; Zhang Z; Sun L; Zou X
Chin Med J (Engl); 2014; 127(8):1600. PubMed ID: 24762619
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients.
Cao Y; Xiao G; Qiu X; Ye S; Lin T
PLoS One; 2014; 9(12):e114008. PubMed ID: 25501361
[TBL] [Abstract][Full Text] [Related]
7. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.
Malik SM; Maher VE; Bijwaard KE; Becker RL; Zhang L; Tang SW; Song P; Liu Q; Marathe A; Gehrke B; Helms W; Hanner D; Justice R; Pazdur R
Clin Cancer Res; 2014 Apr; 20(8):2029-34. PubMed ID: 24573551
[TBL] [Abstract][Full Text] [Related]
8. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
9. EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer.
Wang Y; Zhang J; Gao G; Li X; Zhao C; He Y; Su C; Zhang S; Chen X; Zhang J; Li W; Li B; Zhao J; Hou L; Wu C; Ren S; Zhou C; Zhang J
J Thorac Oncol; 2015 Nov; 10(11):1546-52. PubMed ID: 26352533
[TBL] [Abstract][Full Text] [Related]
10. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
Cappuzzo F; Moro-Sibilot D; Gautschi O; Boleti E; Felip E; Groen HJ; Germonpré P; Meldgaard P; Arriola E; Steele N; Fox J; Schnell P; Engelsberg A; Wolf J
Lung Cancer; 2015 Feb; 87(2):89-95. PubMed ID: 25576294
[TBL] [Abstract][Full Text] [Related]
11. [Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].
Giroux Leprieur E; Wislez M
Bull Cancer; 2016 Feb; 103(2):125-6. PubMed ID: 26822904
[No Abstract] [Full Text] [Related]
12. Successful treatment with alectinib after crizotinib-induced esophageal ulceration.
Yoneshima Y; Okamoto I; Takano T; Enokizu A; Iwama E; Harada T; Takayama K; Nakanishi Y
Lung Cancer; 2015 Jun; 88(3):349-51. PubMed ID: 25837798
[TBL] [Abstract][Full Text] [Related]
13. Crizotinib in the treatment of non--small-cell lung cancer.
Rothschild SI; Gautschi O
Clin Lung Cancer; 2013 Sep; 14(5):473-80. PubMed ID: 23790969
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of crizotinib inhibiting specific molecular pathways in non-small-cell lung carcinoma.
Mirshahidi HR; Mirshahidi S
Expert Rev Anticancer Ther; 2015 Apr; 15(4):375-85. PubMed ID: 25797684
[TBL] [Abstract][Full Text] [Related]
15. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
16. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
[TBL] [Abstract][Full Text] [Related]
17. Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib.
Awad MM; Lax TP; Slawski BR; Shaw AT
J Thorac Oncol; 2014 Nov; 9(11):1726-8. PubMed ID: 25436807
[TBL] [Abstract][Full Text] [Related]
18. Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma.
Gastaud L; Ambrosetti D; Otto J; Marquette CH; Coutts M; Hofman P; Esnault V; Favre G
Lung Cancer; 2013 Nov; 82(2):362-4. PubMed ID: 24001942
[TBL] [Abstract][Full Text] [Related]
19. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.
Kim SJ; Kim DW; Kim TM; Lee SH; Heo DS; Bang YJ
J Clin Oncol; 2012 Jun; 30(16):e147-50. PubMed ID: 22508824
[No Abstract] [Full Text] [Related]
20. Inhibitors of the anaplastic lymphoma kinase.
Mologni L
Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
